Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma

Oncology (Switzerland)

Volumn 84, Issue SUPPL.1, 2013, Pages 82-87

  Nishida, Naoshi ^a,b   Arizumi, Tadaaki ^a   Takita, Masahiro ^a   Nagai, Tomoyuki ^a   Kitai, Satoshi ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Inoue, Tatsuo ^a   Minami, Yasunori ^a   Ueshima, Kazuomi ^a   Sakurai, Toshiharu ^a   Ida, Hiroshi ^b   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

DNA methylation; Epigenetics; Hepatocellular carcinoma; Molecular diagnosis; Tumor suppressor gene

Indexed keywords

ALPHA FETOPROTEIN; APC PROTEIN; DNA; TUMOR DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE SEQUENCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MALE; POLYMERASE CHAIN REACTION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; APC GENE; CANCER DIAGNOSIS; CANCER PATIENT; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; LIMIT OF QUANTITATION; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM; TAQMAN POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; PORTAL VEIN; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC;

EID: 84874394032     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345895     Document Type: Article

References (22)

1. Kim DY, Han K-H: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14.
2. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012; 1: 71-82.
3. Kuang M, Wang Y, Jiang C, Xie XY, Lu MD: A precise safety margin of 1.0 cm is required for best local efficacy of radiofrequency ablation of hepatocellular carcinoma: assessment with a novel three dimensional reconstruction software. Liver Cancer 2012; 1: 125.
4. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
6. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-569.
7. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL: Des- α -carboxy prothrombin and α -fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
8. Nishida N, Goel A: Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011; 12: 130-137.
9. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr: Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-990.
10. Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandell DW, Ikenega M, Imura H, Ishizaki K: Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993; 53: 368-372.
11. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M, et al: Amplification and overexpression of the cyclin d1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-3110.
12. Nishida N: Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis. Histol Histopathol 2010; 25: 647-654.
13. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A: Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012; 56: 994-1003.
14. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A: Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47: 908-918.
15. Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR: Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res 2007; 67: 4586-4594.
16. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H: Wholegenome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760-764.
17. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59: 71-73.
18. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM: Quantitative analysis of tumor-derived methylated p16ink4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 2003; 9: 1047-1052.
19. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM: Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007; 13: 2378-2384.
20. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300.
21. Iizuka N, Oka M, Sakaida I, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Yamashita S, Okita K, Sakata K, Karino Y, Toyota J, Ando E, Ide T, Sata M, Tsunedomi R, Tsutsui M, Iida M, Tokuhisa Y, Sakamoto K, Tamesa T, Fujita Y, Hamamoto Y: Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta 2011; 412: 152-158.
22. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805- 1811.